Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Stock Performance
AUPH traded up $0.21 during trading on Monday, hitting $8.63. The stock had a trading volume of 1,718,073 shares, compared to its average volume of 2,882,071. Aurinia Pharmaceuticals has a twelve month low of $7.70 and a twelve month high of $33.97. The company's 50-day moving average price is $10.32 and its 200 day moving average price is $11.91.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Rating) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.03). Aurinia Pharmaceuticals had a negative return on equity of 38.01% and a negative net margin of 178.32%. During the same quarter last year, the business earned ($0.37) EPS. On average, sell-side analysts predict that Aurinia Pharmaceuticals will post -0.85 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on AUPH. Oppenheimer decreased their target price on Aurinia Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating for the company in a report on Monday, August 8th. Royal Bank of Canada reduced their target price on shares of Aurinia Pharmaceuticals from $22.00 to $18.00 and set an "outperform" rating on the stock in a report on Friday, August 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Aurinia Pharmaceuticals in a report on Thursday, April 28th. StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday, May 23rd. Finally, HC Wainwright lowered their target price on shares of Aurinia Pharmaceuticals from $30.00 to $26.00 and set a "buy" rating for the company in a research note on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $20.40.